Literature DB >> 690512

Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid.

I Makino, S Nakagawa.   

Abstract

Twenty-three patients with gallstones were treated with two dosage levels of ursodeoxycholic acid, 600 mg/day and 150 mg/day. Two to three months after the treatment, the molar percentage of cholesterol in bile significantly decreased (from 7.4 to 4.5 mole % in the 600 mg group and from 7.6 to 4.0 mole % in the 150 mg group), so that bile became unsaturated in most patients in both treatment groups. However, there was no significant difference between the two groups. Biliary ursodeoxycholate increased in proportion to dose, and the sum of ursodeoxycholic acid plus chenodeoxycholic acid in biliary bile acids was over 70%. The was no significant increase in the proportion of lithocholate in bile. The major fecal bile acid of patients receiving ursodeoxycholic acid was lithocholic acid. Serum bile acid concentration rose slightly after 3 months of ursodeoxycholic acid treatment, and the major circulating bile acid became ursodeoxycholic acid. Ursodeoxycholic acid is well absorbed from intestine, undergoes little biotransformation during hepatic passage, and is 7-dehydroxylated by colonic bacteria. The litholytic activity of ursodeoxycholic acid was demonstrated in two patients receiving 450 mg and 150 mg, respectively, of the bile acid per day.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 690512

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

1.  Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition.

Authors:  Akira Honda; Teruo Miyazaki; Junichi Iwamoto; Takeshi Hirayama; Yukio Morishita; Tadakuni Monma; Hajime Ueda; Seiya Mizuno; Fumihiro Sugiyama; Satoru Takahashi; Tadashi Ikegami
Journal:  J Lipid Res       Date:  2019-10-23       Impact factor: 5.922

Review 2.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

Review 3.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

4.  Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones.

Authors:  G Salvioli; R Salati
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

5.  Effect of bile acid feeding on hepatic steroid 12 alpha-hydroxylase activity in hamsters.

Authors:  S Kuroki; T Hoshita
Journal:  Lipids       Date:  1983-11       Impact factor: 1.880

6.  Cholesterol (thermodynamic) activity determinations in bile salt-lecithin-cholesterol systems and cholesterol-rich liquid crystalline mesophase formation.

Authors:  U K Jain; W I Higuchi; C L Liu; P H Lee; N A Mazer
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

7.  Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study.

Authors:  U Leuschner; M Leuschner; J Sieratzki; W Kurtz; K Hübner
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

Review 8.  Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

9.  Effect of small doses of deoxycholic acid on bile cholesterol saturation in patients with liver cirrhosis.

Authors:  P Di Donato; F Carubbi; M Ponz de Leon; N Carulli
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

10.  A treatment of non-ketotic hyperglycinaemia.

Authors:  S Schoos-Barbette; J Gerard; N Francotte; C Lambotte
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.